StockWatch
·

Dishman Carbogen Amcis Ltd Q1 FY27 Results

DCALQ1 FY27 Results
Filing
Result:Poor· Market: CrashedTurnaroundCost ledMargin squeeze
MetricValueChangeQ1 FY26
Revenue677.64 Cr4.3%
Total Income695.80 Cr5.0%
Expenditure745.33 Cr7.8%
PBT-51.22 Cr232.4%
Net Profit-57.88 Cr347.2%
OPM8.62%10.87pp
NPM-8.32%11.51pp
EPS3.69147.7%
View full financials

Consolidated PAT swung to a Rs57.88 Cr loss (not a turnaround-to-profit) on a 4.3% YoY revenue decline, with OPM collapsing to 8.62% from 19.49% driven by employee-cost inflation rather than the QIP one-off, marking clear core deterioration for a pharma CDMO.

Q1 FY-2027 RESULTS · DCAL

Dishman Carbogen swings to Rs57.9 Cr consolidated loss as margins crash to 8.9% YoY

PAT -347.24% YoY · revenue -4.29% · margins compressing

14 Aug 2026 · 3 min read
Revenue

₹677.64 Cr

-4.29% YoY

PAT (consolidated)

₹-57.88 Cr

-347.24% YoY

Net margin

-8.32%

-11.5pp YoY

EPS

₹-3.69

Dishman Carbogen Amcis (consolidated, the primary basis) posted a net loss of Rs57.88 Cr in Q1 FY27, reversing a Rs23.41 Cr profit in Q1 FY26 and a Rs21.74 Cr profit in Q4 FY26 - a turnaround to loss on both a YoY and QoQ basis, with EPS at -Rs3.69 versus +Rs1.49 a year ago. Revenue from operations fell 4.3% YoY to Rs677.64 Cr and 20.4% QoQ from Rs851.40 Cr (Q4 is seasonally the group's strongest quarter). Operating margin (EBITDA/revenue, company-reported) collapsed to 8.87% from 19.87% YoY and 19.14% QoQ, and net margin swung to -8.54% from +3.31% YoY - a sharp compression on both lines.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹677.64 Cr-4.3%
Expenses₹745.33 Cr+7.8%
PAT₹-57.88 Cr-366.14%-347.24%
Net margin-8.32%-11.5pp
EPS₹-3.69-347.7%

The squeeze sits mainly on employee costs, not the one-off item: employee benefits expense rose to 57.4% of revenue (Rs389.10 Cr) from 49.7% YoY (Rs351.90 Cr) even as revenue declined, the single largest driver of the margin collapse. Net material cost (cost of materials consumed adjusted for inventory changes) also rose to roughly 16.9% of revenue from 13.9% YoY. A Rs1.69 Cr exceptional charge for abandoned QIP transaction costs hit PBT on both standalone and consolidated statements, but pre-exceptional operating profit was already negative Rs49.53 Cr consolidated - adjusting both years for their respective exceptional items still shows a swing from an adjusted profit of roughly Rs26 Cr a year ago to an adjusted loss of roughly Rs56 Cr now, so the one-off is not what drove this into the red. Standalone (the India entity) was weaker still, with a net loss of Rs23.91 Cr versus a Rs2.67 Cr profit YoY on just Rs57.08 Cr of revenue and operating margin of -20.71%, underscoring that India operations remain a small, currently loss-making sliver of a group whose scale sits in the European/Swiss subsidiaries.

162.57176.22189.87203.51217.16190.6605-1106-0406-3007-2308-14Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹190.66, down 1.8% over the past month of trading.

₹ Cr
-72.66-21.7629.1580.054.63Q3 FY25rev ₹682 Cr43.09Q4 FY25rev ₹716 Cr23.41Q1 FY26rev ₹708 Cr65.27Q2 FY26rev ₹653 Cr-12.97Q3 FY26rev ₹720 Cr-57.88Q1 FY27rev ₹678 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (3 FY-2026 call)
Management reiterates its full-year FY26 EBITDA margin guidance of 19.5-20%, anticipating a stronger Q4 to offset a weaker Q3 product mix. The company projects a significant long-term ramp-up, targeting INR 500 crores in revenue from its India operations within 12-18 months, driven by a substantial INR 1,200 crore RFP

This quarter: missed

No specific street consensus for this quarter surfaced in available coverage; broker commentary instead frames a broader FY27 earnings-recovery thesis built on easing input costs and a richer revenue mix, a thesis this print does not support in its first quarter. Against management's own prior guidance - a Q3 FY26 concall target of restoring consolidated EBITDA margin to 25-26% within two years, alongside a French-facility breakeven goal for FY27 - this quarter's 8.87% margin is a clear miss and a step in the wrong direction from that trajectory; the FY26 full-year margin guidance of 19.5-20% itself was roughly met in Q4 FY26 (19.14%) but that guidance window has now closed. Management's own framing in the filing (note 9) attributes the exceptional charge to abandoning a planned QIP equity raise 'due to adverse market conditions and an altered fundraising plan' - consistent with the company instead raising debt this quarter (Rs18 Cr of NCDs placed on June 9) and immediately after quarter-end (board approval for a further Rs75 Cr NCD issuance on August 12); consolidated debt-equity rose to 0.48x from 0.35x YoY, evidence of the pivot from equity to debt funding.

  • W1

    Whether Q2 FY27 employee-cost ratio normalizes back toward the ~50% of revenue seen a year ago, the single largest driver of this quarter's margin collapse.

  • W2

    Progress toward management's prior target (Q3 FY26 concall) of restoring consolidated EBITDA margin to 25-26% within two years - Q1 FY27's 8.87% print is a sharp step away from that trajectory.

  • W3

    Utilization and terms of the Rs75 Cr NCD issuance approved Aug 12, and whether the company returns to equity fundraising after abandoning its QIP this quarter.

Both standalone and consolidated statements present and legible; arithmetic ties out (totalIncome = revenue+otherIncome; PAT = PBT-tax on both). Exceptional item of Rs1.69 Cr (QIP transaction costs written off, note 9) hits both bases and is common to both periods being compared (prior year had Rs2.65 Cr exceptional), so it does not materially explain the swing to loss. Consolidated tax expense of Rs6.66 Cr despite a pretax loss is unusual (likely no deferred tax asset recognized on India-entity losses while profitable overseas units still owe tax) - flagged, not treated as an error.

Informational and educational content only. Not investment advice.

Dishman Carbogen Amcis Ltd (DCAL) Q1 FY27 Results — StockWatch